OSAKA — Drugstore chain Daikoku said Thursday it has asked the Tokyo District Court to issue a provisional ruling to get drugmaker Taisho Pharmaceutical Co. to resume supplying products to its stores.

Taisho Pharmaceutical has stopped supplying Daikoku and last week filed a damages suit against the retailer for 100 million yen on the grounds that a recent sales campaign had revealed Taisho’s wholesale prices.

The Osaka-based Daikoku claims the halted product supply is threatening its entire business and that the drugmaker filed the suit with the preconception that selling its products at cost was a problem.

Daikoku is considering appealing to the Fair Trade Commission that Taisho’s moves violate the Antimonopoly Law.

Taisho claims that five Daikoku group firms began selling its products, including the popular men’s hair-growth promoter RiUP, at wholesale prices. The drugmaker claims this leaked trade secrets by revealing its production costs and put the company at a competitive disadvantage.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.